Maraviroc Patent Expiration
Maraviroc is Used for treating patients infected with CCR5-tropic HIV-1. It was first introduced by Viiv Healthcare Co
Maraviroc Patents
Given below is the list of patents protecting Maraviroc, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Selzentry |
US7368460 (Pediatric) | Tropane derivatives useful in therapy |
May 25, 2023
(Expired) | Viiv Hlthcare |
| Selzentry | US7368460 | Tropane derivatives useful in therapy |
Nov 25, 2022
(Expired) | Viiv Hlthcare |
| Selzentry |
US6667314 (Pediatric) | Tropane derivatives useful in therapy |
Feb 06, 2022
(Expired) | Viiv Hlthcare |
| Selzentry |
US7576097 (Pediatric) | Tropane derivatives useful in therapy |
Nov 25, 2021
(Expired) | Viiv Hlthcare |
| Selzentry | US6667314 | Tropane derivatives useful in therapy |
Aug 06, 2021
(Expired) | Viiv Hlthcare |
| Selzentry | US6667314 | Tropane derivatives useful in therapy |
Aug 06, 2021
(Expired) | Viiv Hlthcare |
| Selzentry | US7576097 | Tropane derivatives useful in therapy |
May 25, 2021
(Expired) | Viiv Hlthcare |
| Selzentry | US7576097 | Tropane derivatives useful in therapy |
May 25, 2021
(Expired) | Viiv Hlthcare |
| Selzentry | US6586430 | CCR5 modulators |
Dec 01, 2019
(Expired) | Viiv Hlthcare |
| Selzentry | US6586430 | CCR5 modulators |
Dec 01, 2019
(Expired) | Viiv Hlthcare |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Maraviroc's patents.
Latest Legal Activities on Maraviroc's Patents
Given below is the list recent legal activities going on the following patents of Maraviroc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Sep, 2020 | US7576097 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Oct, 2019 | US7368460 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Jun, 2010 | US6667314 |
| Notice of Final Determination -Eligible | 23 Feb, 2010 | US6667314 |
| FDA Final Eligibility Letter Critical | 30 Sep, 2009 | US6667314 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Aug, 2009 | US7576097 |
| Recordation of Patent Grant Mailed Critical | 18 Aug, 2009 | US7576097 |
| Email Notification Critical | 30 Jul, 2009 | US7576097 |
| Issue Notification Mailed Critical | 29 Jul, 2009 | US7576097 |
| Application Is Considered Ready for Issue Critical | 16 Jul, 2009 | US7576097 |
Maraviroc's Family Patents
Explore Our Curated Drug Screens
Maraviroc Generic API Manufacturers
Several generic applications have been filed for Maraviroc. The first generic version for Maraviroc was by Hetero Labs Ltd Unit Iii and was approved on Feb 7, 2022. And the latest generic version is by I 3 Pharmaceuticals Llc and was approved on Aug 17, 2023.
Given below is the list of companies who have filed for Maraviroc generic, along with the locations of their manufacturing plants worldwide.
1. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Feb 7, 2022 |
| 300MG | tablet | Prescription | ORAL | AB | Feb 7, 2022 |
2. I 3 PHARMS
I 3 Pharmaceuticals Llc has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by I 3 Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Aug 17, 2023 |
| 300MG | tablet | Prescription | ORAL | AB | Aug 17, 2023 |